REGNRegeneron PharmaceuticalsSigning up patients
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
High Risk Smoldering Multiple Myeloma (HR-SMM)
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 270 (planned)
- Started
- May 21, 2026
- Main results expected
- Jul 27, 2033
- Fully finished
- Jul 27, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Clinical Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) criteria
Measured over: Up to 5 years
Biochemical PFS per IMWG criteria
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07393282 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC